AZN.Lライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 7月 2024 @ 18:13):
Our systems believe the stock currently is undervalued by 0.01% compare to its pairs and should correct upwards.

Stats
本日の出来高	73 508
平均出来高	2.21M
時価総額	190.79B
EPS	£1.410 ( Q1 \| 2024-03-31 )
次の収益日	( £1.530 ) 2024-07-24
Last Dividend	£123.25 ( 2024-02-22 )
Next Dividend	£0 ( N/A )
P/E	38.46 (Sector) 0 (Industry) 0
ATR14	£4.41 (0.04%)

AMYT.L -11.73%

APH.L 0.07%

AVCT.L -2.70%

AZN.L -0.40%

BMK.L 2.34%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -0.80%

DPH.L 0.05%

EAH.L 3.20%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.98%

FUM.L 0.27%

GDR.L 3.33%

GNS.L 1.44%

GSK.L -0.49%

HCM.L -0.36%

HEMO.L -2.90%

HIK.L -0.53%

IMM.L 4.81%

INDV.L -0.40%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -5.00%

OBD.L 3.33%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.63%

OVB.L -2.22%

OXB.L 1.69%

PRM.L -4.82%

PRTC.L -0.23%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 10.11%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 4.05%

STX.L 2.70%

TILS.L 8.33%

TRX.L -2.06%

VAL.L 0.00%

VEC.L 0.00%

相関 (AI algo v.1.1b): Undervalued: 0.01% £12 308 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: -0.21 (neutral)

短: -0.65 (weak negative)

Signal:(46.671) Neutral

AstraZeneca PLC 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

AstraZeneca PLC 相関 - 通貨/商品

-0.51
( weak negative )

-0.45
( neutral )

-0.06
( neutral )

-0.40
( neutral )

0.30
( neutral )

0.65
( moderate )

AstraZeneca PLC 財務諸表

Annual	2023
収益:	£45.81B
総利益:	£37.54B (81.95 %)
EPS:	£3.84

FY	2023
収益:	£45.81B
総利益:	£37.54B (81.95 %)
EPS:	£3.84

FY	2022
収益:	£44.35B
総利益:	£31.96B (72.06 %)
EPS:	£2.12

FY	2021
収益:	£37.42B
総利益:	£24.98B (66.76 %)
EPS:	£0.0854

Financial Reports:

No articles found.

AstraZeneca PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£62.90 (N/A)	£0 (N/A)	£135.30 (N/A)	£0 (N/A)	£56.54 (N/A)	£0 (N/A)	£123.25 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

AstraZeneca PLC Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.81 - Stable (36.12%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£6.94	1993-09-20
Last Dividend	£123.25	2024-02-22
Next Dividend	£0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	62	--
Total Paid Out	£2 628.66	--
Avg. Dividend % Per Year	1.63%	--
Score	4.95	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.81
Div. Directional Score	8.91	--

Next Divdend (Est)
(2024-07-02)

£126.96 Estimate 18.69 %

Dividend Stability

0.50 Below Average

Dividend Score

4.95

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1993	£0	0.00%
1994	£0	0.00%
1995	£0	0.00%
1996	£0	0.00%
1997	£0	0.00%
1998	£0	0.00%
1999	£0	0.00%
2000	£0	0.00%
2001	£0	0.00%
2002	£0	0.00%
2003	£0	0.00%
2004	£0	0.00%
2005	£0	0.00%
2006	£0	0.00%
2007	£0	0.00%
2008	£0	0.00%
2009	£0	0.00%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£0	0.00%
2019	£170.15	2.79%
2020	£166.98	2.18%
2021	£144.82	1.95%
2022	£170.91	2.02%
2023	£191.84	1.66%
2024	£123.25	1.14%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
22 Feb 2024	£123.25	30 Nov -0001	30 Nov -0001	30 Nov -0001
10 Aug 2023	£56.54	30 Nov -0001	11 Aug 2023	11 Sep 2023
23 Feb 2023	£135.30	09 Feb 2023	24 Feb 2023	27 Mar 2023
11 Aug 2022	£62.90	29 Jul 2022	12 Aug 2022	12 Sep 2022
24 Feb 2022	£108.01	10 Feb 2022	25 Feb 2022	28 Mar 2022
12 Aug 2021	£46.82	29 Jul 2021	13 Aug 2021	13 Sep 2021
25 Feb 2021	£98.00	11 Feb 2021	26 Feb 2021	29 Mar 2021
13 Aug 2020	£53.26	24 Oct 2019	14 Aug 2020	14 Sep 2020
27 Feb 2020	£113.72	24 Oct 2019	28 Feb 2020	30 Mar 2020
08 Aug 2019	£59.33	08 Nov 2018	09 Aug 2019	09 Sep 2019
28 Feb 2019	£110.82	08 Nov 2018	01 Mar 2019	27 Mar 2019
09 Aug 2018	£53.29	09 Nov 2017	10 Aug 2018	10 Sep 2018
15 Feb 2018	£95.28	09 Nov 2017	16 Feb 2018	19 Mar 2018
10 Aug 2017	£53.05	02 Feb 2017	11 Aug 2017	11 Sep 2017
16 Feb 2017	£120.51	16 Nov 2016	17 Feb 2017	20 Mar 2017
11 Aug 2016	£53.03	04 Feb 2016	12 Aug 2016	12 Sep 2016
18 Feb 2016	£91.59	04 Feb 2016	19 Feb 2016	21 Mar 2016
13 Aug 2015	£36.84	30 Jul 2015	14 Aug 2015	14 Sep 2015
19 Feb 2015	£81.07	06 Nov 2014	20 Feb 2015	23 Mar 2015
13 Aug 2014	£31.76	31 Jul 2014	15 Aug 2014	15 Sep 2014

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
DNA2.L	Dividend Royal	2024-04-18	Quarterly	9	16.51%	8.69
MPLS.L	Dividend Royal	2024-04-11	Quarterly	7	12.84%	8.67
FAIR.L	Dividend Royal	2024-05-30	Quarterly	9	10.77%	8.67
BGLF.L	Dividend Royal	2024-05-02	Quarterly	9	10.03%	8.50
SEPL.L	Dividend Royal	2024-05-30	Quarterly	11	10.34%	8.34
DNA3.L	Dividend Royal	2024-04-18	Quarterly	12	14.16%	8.31
DEC.L	Dividend Royal	2024-08-29	Quarterly	8	59.83%	7.91
AA4.L	Dividend Royal	2024-04-11	Quarterly	9	12.37%	7.88
IMB.L	Dividend Royal	2024-08-22	Quarterly	28	7.10%	7.51
FBH.L	Dividend Royal	2024-05-02	Annually	22	11.26%	7.46

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.133	1.500	7.34	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0619	1.200	7.94	9.52	[0 - 0.3]
returnOnEquityTTM	0.168	1.500	9.25	10.00	[0.1 - 1]
payoutRatioTTM	0.706	-1.000	2.94	-2.94	[0 - 1]
currentRatioTTM	0.886	0.800	-0.572	-0.458	[1 - 3]
quickRatioTTM	0.661	0.800	-0.820	-0.656	[0.8 - 2.5]
cashRatioTTM	0.271	1.500	9.60	10.00	[0.2 - 2]
debtRatioTTM	0.338	-1.500	4.37	-6.56	[0 - 0.6]
interestCoverageTTM	5.33	1.000	9.14	9.14	[3 - 30]
operatingCashFlowPerShareTTM	6.26	2.00	7.91	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.73	2.00	8.13	10.00	[0 - 20]
debtEquityRatioTTM	0.923	-1.500	6.31	-9.46	[0 - 2.5]
grossProfitMarginTTM	0.820	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.184	1.000	8.32	8.32	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.281	1.000	9.55	9.55	[0.2 - 2]
assetTurnoverTTM	0.465	0.800	-0.230	-0.184	[0.5 - 2]
Total Score				11.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	38.27	1.000	6.24	0	[1 - 100]
returnOnEquityTTM	0.168	2.50	9.52	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.73	2.00	8.76	10.00	[0 - 30]
dividendYielPercentageTTM	1.149	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.26	2.00	7.91	10.00	[0 - 30]
payoutRatioTTM	0.706	1.500	2.94	-2.94	[0 - 1]
pegRatioTTM	168.99	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.204	1.000	7.41	0	[0.1 - 0.5]
Total Score				6.81

AstraZeneca PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.